Proteotype Diagnostics initiated new clinical work to support CE-IVDR submission for Enlighten, its multicancer early detection (MCED) blood test. The company also planned an additional study to optimize its platform and said it is preparing to raise about £5 million, seeking a lead investor. CEO Wesley Sukdao described Enlighten’s underlying immunodiagnostic approach, which measures multidimensional amino-acid residue biomarkers in plasma proteome patterns. The company’s prior work cited in the coverage reported 78% cancer detection in a validation dataset without misclassifying healthy participants. For MCED developers, the update shows continued regulatory preparation and iterative evidence generation to support market access in Europe.